NorthStrive Biosciences Amends License for EL-32 and EL-22 Clinical Milestones
NorthStrive Biosciences filed a third amendment to its license with MOA Life Plus, updating development timelines and milestones for myostatin inhibitors EL-32 and EL-22. The revision aligns human clinical schedules with regulatory expectations to advance muscle preservation programs alongside GLP-1 therapies.
1. Amendment Overview
On March 27, NorthStrive Biosciences executed a third amendment to its existing license with MOA Life Plus covering myostatin inhibitors EL-32 and EL-22, extending partnership terms and reaffirming development commitments.
2. Updated Development Milestones
The amendment revises key clinical development timelines, resetting milestone deadlines and aligning human trial schedules with both parties’ R&D strategies and regulatory submission plans.
3. Expected Impact on Pipeline
By adjusting timelines, the agreement aims to streamline muscle preservation programs in combination with GLP-1 therapies, potentially accelerating proof-of-concept data and enhancing asset valuation.
4. Company and Partner Profiles
NorthStrive Biosciences, a PMGC Holdings subsidiary, focuses on aesthetic and metabolic therapies, while MOA Life Plus brings global biotech expertise to co-develop these assets.